Patents by Inventor Andrew Boyd
Andrew Boyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100041699Abstract: The invention relates to a microcrystalline form of a compound which is an inhibitor of PGD2 at the CRTH2 receptor. The microcrystalline form is obtained from a simple chemical reaction without the need for a milling process.Type: ApplicationFiled: March 1, 2006Publication date: February 18, 2010Applicant: OXAGEN LIMITEDInventors: Edward Andrew Boyd, Frederick Arthur Brookfield, Christopher James Brennan, Christopher Francis Palmer, Leigh Andre Pearcey, James Matthew Lovell
-
Patent number: 7662839Abstract: A compound of formula (I): or a salt, or chemically protected form thereof, wherein: R5 is an optionally substituted phenyl; A is ?wherein Q is N; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl, and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl, and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: Where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm-alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally, when RP3 is —Cm-alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionalType: GrantFiled: December 5, 2007Date of Patent: February 16, 2010Assignee: Asterand UK LimitedInventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
-
Publication number: 20090298899Abstract: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.Type: ApplicationFiled: December 30, 2008Publication date: December 3, 2009Inventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
-
Patent number: 7582672Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: GrantFiled: October 22, 2004Date of Patent: September 1, 2009Assignee: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Eric R. Pettipher, Michael George Hunter, Mark Whittaker, Chris Palmer
-
Publication number: 20090023788Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: ApplicationFiled: September 17, 2008Publication date: January 22, 2009Applicant: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Eric Roy Pettipher, Michael George Hunter, Mark Whittaker, Chris Palmer
-
Publication number: 20090018139Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: ApplicationFiled: September 17, 2008Publication date: January 15, 2009Applicant: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Publication number: 20090018338Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: ApplicationFiled: September 17, 2008Publication date: January 15, 2009Applicant: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Publication number: 20090018138Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: ApplicationFiled: September 17, 2008Publication date: January 15, 2009Applicant: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Publication number: 20090012082Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: ApplicationFiled: November 3, 2005Publication date: January 8, 2009Applicant: CURIS, INC.Inventors: Olivin M. Guicherit, Edward Andrew Boyd, Judith Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. MacKinnon
-
Publication number: 20080207740Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.Type: ApplicationFiled: August 20, 2007Publication date: August 28, 2008Applicant: Curis, Inc.Inventors: Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
-
Publication number: 20080203831Abstract: A primary disc and the secondary discs are each fitted with magnetic means, typically in the form of permanent magnets of the same polarity, located along a radial line from the centre point of the discs, and arranged generally transverse to the axis of rotation of the respective disc. As shown in the drawings, these magnets are also located at or adjacent to the periphery of the disc(s). The magnets are embedded into each of the primary and secondary discs such that the faces of the magnets are flush with the exterior faces of the primary and secondary discs. In the embodiment, each of the magnets embedded in the primary disc has a North pole which is aligned with a North pole of a magnet embedded in the secondary disc. Each of the South pole of those magnets embedded in the primary disc has a South pole which is aligned with a South pole of a magnet embedded in the other secondary disc.Type: ApplicationFiled: April 10, 2006Publication date: August 28, 2008Inventor: Andrew Boyd French
-
Patent number: 7414067Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.Type: GrantFiled: March 24, 2004Date of Patent: August 19, 2008Assignees: Merck & Co. Inc., Evotec OAIInventors: Edward Andrew Boyd, Michael H. Fisher, Maria L. Garcia, Gregory J. Kaczorowski, Peter T. Meinke, William H. Parsons, Stephen Price, John Stibbard
-
Publication number: 20080119526Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3Type: ApplicationFiled: December 5, 2007Publication date: May 22, 2008Applicant: PHARMAGENE LABORATORIES LIMITEDInventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
-
Patent number: 7326732Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN? is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and tType: GrantFiled: February 11, 2005Date of Patent: February 5, 2008Assignee: Pharmagene Laboratories LimitedInventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd, Shirley Ann Brunton
-
Patent number: 7300929Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: April 4, 2003Date of Patent: November 27, 2007Assignee: Curis, Inc.Inventors: Anthony David Baxter, Edward Andrew Boyd, Oivin Guicherit, Stephen Price, Lee L. Rubin
-
Publication number: 20060277284Abstract: An improved distributed operating system over a network of computer systems is described. Existing distributed operating systems have transmission performance limitations dictated by their inability to (1) reliably handle transient communication failures and rapid node reboots, (2) provide a transmission protocol that adapts to link reliability, and (3) allow transmissions to occur over an arbitrary combinations of communication links. The systems and methods described herein solve these problems by providing a reliable node-to-node session protocol that offers high performance message delivery and multi-interface management and support. This is done by transmitting all data between two nodes of the operating system over a single connection that may dynamically exploit multiple interfaces between the nodes.Type: ApplicationFiled: June 3, 2005Publication date: December 7, 2006Inventor: Andrew Boyd
-
Publication number: 20060277285Abstract: An improved distributed operating system over a network of computer systems is described. Existing distributed operating systems have transmission performance limitations dictated by their inability to (1) reliably handle transient communication failures and rapid node reboots, (2) provide a transmission protocol that adapts to link reliability, and (3) allow transmissions to occur over an arbitrary combinations of communication links. The systems and methods described herein solve these problems by providing a reliable node-to-node session protocol that offers high performance message delivery and multi-interface management and support. This is done by transmitting all data between two nodes of the operating system over a single connection that may dynamically exploit multiple interfaces between the nodes.Type: ApplicationFiled: June 3, 2005Publication date: December 7, 2006Inventor: Andrew Boyd
-
Patent number: 7115653Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.Type: GrantFiled: September 17, 2002Date of Patent: October 3, 2006Assignee: Curis, Inc.Inventors: Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee L. Rubin, John Harry Alexander Stibbard
-
Publication number: 20060140957Abstract: Methods and compositions for modulating ephrin/Eph receptor-mediated cell adhesion and/or cell repulsion are provided, particularly in relation to preventing, inhibiting or delaying tumour cell metastasis through modulation of Eph receptor-ephrin binding interactions and subsequent Eph receptor signalling. Particular agents useful according to the invention are agents which interfere with a ephrin-Eph receptor binding such as soluble ephrins and Eph receptors and antibodies directed to ephrins and Eph receptors, ephrin-cytotoxic drug conjugates which kill tumour cells, metalloprotease inhibitors and inhibitors of protein tyrosine phosphatase activity.Type: ApplicationFiled: February 9, 2004Publication date: June 29, 2006Inventors: Martin Lackmann, Sabine Wimmer-Kleikamp, Andrew Scott, Christopher Vearing, Andrew Boyd
-
Publication number: 20050181981Abstract: The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.Type: ApplicationFiled: April 7, 2005Publication date: August 18, 2005Applicants: The Walter and Eliza Hall Institute of Medical Research, The Council of the Queensland Institute of Medical Research, The University of MelbourneInventors: Perry Bartlett, Lynne Hartley, Mark Pouzzotto, Trevor Kilpatrick, Frank Kontgen, Jason Coonan, Ursula Greferath, Andrew Boyd, Mirella Dottori, Mary Galea, George Paxinos, Mark Murphy